Centogene (NASDAQ:CNTG) Earns “Outperform” Rating from Svb Leerink

Svb Leerink restated their outperform rating on shares of Centogene (NASDAQ:CNTG) in a research report sent to investors on Monday, Zacks.com reports. Svb Leerink also issued estimates for Centogene’s Q3 2019 earnings at ($18.47) EPS, Q4 2019 earnings at ($0.18) EPS, FY2019 earnings at ($4.37) EPS, Q1 2020 earnings at ($0.25) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.26) EPS, Q4 2020 earnings at ($0.30) EPS, FY2020 earnings at ($1.09) EPS, Q1 2021 earnings at ($0.19) EPS, Q2 2021 earnings at ($0.17) EPS, Q3 2021 earnings at ($0.15) EPS and FY2021 earnings at ($0.61) EPS.

Several other analysts have also weighed in on CNTG. Evercore ISI started coverage on Centogene in a report on Monday. They issued an outperform rating and a $17.00 price objective for the company. Robert W. Baird assumed coverage on Centogene in a report on Tuesday. They set an outperform rating and a $15.00 target price on the stock. Finally, BTIG Research assumed coverage on shares of Centogene in a research report on Monday. They issued a buy rating and a $18.00 price target on the stock.

NASDAQ CNTG traded down $0.94 on Monday, reaching $11.81. 544 shares of the stock traded hands, compared to its average volume of 63,300. Centogene has a 12 month low of $11.61 and a 12 month high of $15.59.

Centogene Company Profile

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

See Also: Understanding each part of a balance sheet

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit